Albireo Stock Analysis


USD 23.78  0.84  3.66%   

The latest price rise of Albireo Pharma could raise concerns from institutional investors as the firm is trading at a share price of 23.78 on 147,420 in volume. The company executives may have good odds in positioning the firm resources to exploit market volatility in January. The stock standard deviation of daily returns for 90 days investing horizon is currently 4.77. This high volatility is attributed to the latest market swings and not-so-good earnings reports for some of the Albireo Pharma partners.
Please continue to Trending Equities.
The Albireo Pharma stock analysis report makes it easy to digest most publicly released information about Albireo Pharma and get updates on important government artifacts, including earning estimates, SEC corporate filings, and announcements. Albireo Stock analysis module also helps to analyze the Albireo Pharma price relationship with some important fundamental indicators such as market cap and management efficiency.

Albireo Stock Analysis Notes

About 97.0% of the company shares are held by institutions such as insurance companies. The book value of Albireo Pharma was presently reported as 4.84. The company recorded a loss per share of 1.7. Albireo Pharma last dividend was issued on the 4th of November 2016. The entity had 1:30 split on the 4th of November 2016. Albireo Pharma, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of novel bile acid modulators to treat orphan pediatric liver diseases and other liver or gastrointestinal diseases and disorders. Albireo Pharma, Inc. is headquartered in Boston, Massachusetts. Albireo Pharma operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 130 people. For more info on Albireo Pharma please contact Ronald Cooper at 857 254 5555 or go to

Albireo Pharma Investment Alerts

Many investors view ongoing market volatility as an opportunity to purchase more stocks at a favorable price or short it to generate a bearish trend profit opportunity. If you are one of those investors, make sure you clearly understand the position you are entering. Albireo Pharma's investment alerts are automatically generated signals that are significant enough to either complement your investing judgment regarding Albireo Pharma or challenge it. These alerts can help you understand what you are buying and avoid costly mistakes.
Albireo Pharma appears to be risky and price may revert if volatility continues
The company reported the previous year's revenue of 40.58 M. Net Loss for the year was (34.03 M) with profit before overhead, payroll, taxes, and interest of 39.22 M.
Albireo Pharma currently holds about 180.97 M in cash with (107.56 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 9.23.
Albireo Pharma has a frail financial position based on the latest SEC disclosures
Over 97.0% of the company shares are held by institutions such as insurance companies
Latest headline from MacroaxisInsider: Sale by Weisman Scott of 3851 shares of Albireo Pharma

Albireo Pharma Upcoming and Recent Events

Earnings reports are used by Albireo Pharma to provide an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Every quarterly earnings report provides investors with three things: an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Albireo Pharma previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
Upcoming Quarterly Report24th of February 2022
Next Financial Report5th of May 2022
Next Fiscal Quarter End31st of December 2021
Next Fiscal Year End24th of February 2022
Last Quarter Report30th of September 2021
Last Financial Announcement31st of December 2020

Albireo Largest EPS Surprises

Earnings surprises can significantly impact Albireo Pharma's stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
Fiscal Date
Estimated EPS
Reported EPS
View All Earnings Estimates

Albireo Pharma SEC Filings

SEC filings are important regulatory documents required of all public companies to provide to potential investors. Albireo Pharma prospectus issued under the guidelines of SEC is a legal declaration of facts and statements to ensure that Albireo Pharma investors are not misled. SEC filings are required by law to meet strict transparency standards and other important legal constraints. Although many companies may choose careful wording to disguise some material information, SEC filings make crucial Albireo Pharma specific information freely available to individual and institutional investors to make a timely investment decision.
22nd of August 2022
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
15th of August 2022
Financial Statements and Exhibits. Results of Operations and Financial Condition. Termination of a Material Definitive Agreement. Entry into a Material Definitive Agreement
10th of August 2022
Financial Statements and Exhibits. Regulation FD Disclosure. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
29th of July 2022
Termination of a Material Definitive Agreement
17th of June 2022
Submission of Matters to a Vote of Security Holders
16th of May 2022
Financial Statements and Exhibits. Results of Operations and Financial Condition
7th of March 2022
Unclassified Corporate Event
1st of March 2022
Financial Statements and Exhibits. Results of Operations and Financial Condition

Albireo Stock Institutional Investors

Have you ever been surprised when a price of an equity instrument such as Albireo Pharma is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Albireo Pharma backward and forwards among themselves. Albireo Pharma's institutional investor refers to the entity that pools money to purchase Albireo Pharma's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
Security TypeSharesValue
Zurcher Kantonalbank Zurich CantonalbankCommon Shares4.9 K95 K
Zurcher Kantonalbank Zurich CantonalbankCommon Shares4.9 K97 K
Zurcher Kantonalbank Zurich CantonalbankCommon Shares4.9 K146 K
Zurcher Kantonalbank Zurich CantonalbankCommon Shares4.9 K114 K
Wolverine Trading LlcCall Options17.3 K307 K
Wipfli Financial Advisors LlcCommon Shares56411 K
Winton Group LtdCommon Shares13.2 K337 K
Wells Fargo CompanyCommon SharesK59 K
Note, although Albireo Pharma's institutional investors appear to be way more sophisticated than retail investors, it remains unclear if professional active investment managers can reliably enhance risk-adjusted returns by an amount that exceeds fees and expenses.

Albireo Market Capitalization

The company currently falls under 'Small-Cap' category with current market capitalization of 486.48 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Albireo Pharma's market, we take the total number of its shares issued and multiply it by Albireo Pharma's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and these looking for more risk prefer small-cap and mid-cap equities.

Albireo Profitablity

Albireo Pharma's profitability indicators refer to fundamental financial ratios that showcase Albireo Pharma's ability to generate income relative to its revenue or operating costs. If, let's say, Albireo Pharma is currently losing money, the management's focus should be on how to reverse that trend. However, when revenue exceeds expenses, Albireo Pharma's executives or investors may be in less hurry to break that information down - which is where profitability analysis comes into play. Gaining a greater understanding of Albireo Pharma's profitability requires more research than a typical breakdown of Albireo Pharma's financial statements. By doing a profitability analysis, companies can identify areas needing attention, and investors can make a profitable trade.
The company has Profit Margin (PM) of (2.29) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of (2.15) %, which suggests for every $100 dollars of sales, it generated a net operating loss of -0.02.
Last ReportedProjected for 2022
Return on Investment(65.60) (70.78) 
Return on Average Assets(11.58) (12.50) 
Return on Average Equity(19.07) (20.58) 
Return on Invested Capital 23.05  19.26 
Return on Sales(0.49) (0.53) 

Management Efficiency

The entity has return on total asset (ROA) of (0.2494) % which means that it has lost $0.2494 on every $100 spent on asset. This is way below average. Similarly, it shows return on stockholders equity (ROE) of (0.9308) %, meaning that it created substantial loss on money invested by shareholders. Albireo Pharma management efficiency ratios could be used to measure how well albireo pharma manages its routine affairs as well as how well it operates its assets and liabilities. The value of Return on Investment is estimated to slide to -70.78. The value of Return on Average Assets is estimated to slide to -12.5. Albireo Pharma Net Current Assets as percentage of Total Assets are quite stable at the moment as compared to the past year. The company's current value of Net Current Assets as percentage of Total Assets is estimated at 85.25. Tangible Assets Book Value per Share is expected to rise to 15.21 this year, although the value of Goodwill and Intangible Assets will most likely fall to about 16.5 M.
Last ReportedProjected for 2022
Book Value per Share 9.14  9.38 
Enterprise Value over EBIT(10.00) (10.26) 
Enterprise Value over EBITDA(9.90) (10.16) 
Price to Book Value 2.56  2.49 
Tangible Assets Book Value per Share 14.82  15.21 
Enterprise Value196.3 M165.7 M
Tangible Asset Value284.8 M307.3 M

Technical Drivers

As of the 3rd of December, Albireo Pharma shows the risk adjusted performance of 0.1853, and Mean Deviation of 3.31. Albireo Pharma technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices. Put another way, you can use this information to find out if the firm will indeed mirror its model of historical prices and volume momentum, or the prices will eventually revert. We have analyzed nineteen technical drivers for Albireo Pharma, which can be compared to its rivals. Please confirm Albireo Pharma information ratio, and the relationship between the downside deviation and value at risk to decide if Albireo Pharma is priced correctly, providing market reflects its regular price of 23.78 per share. Given that Albireo Pharma has jensen alpha of 0.4591, we suggest you to validate Albireo Pharma's prevailing market performance to make sure the company can sustain itself at a future point.

Albireo Pharma Price Movement Analysis

Start Value
Offset on Reverse
AF Init Long
AF Long
AF Max Long
AF Init Short
AF Short
AF Max Short
Execute Study
The output start index for this execution was one with a total number of output elements of sixty. The Extended Parabolic SAR indicator is used to determine the direction of Albireo Pharma's momentum and the point in time when it has higher than normal probability of directional change. It has more input parameters than standard Parabolic SAR indicator.

Albireo Pharma Insider Trading Activities

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Albireo Pharma insiders, such as employees or executives, is commonly permitted as long as it does not rely on Albireo Pharma's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Albireo Pharma insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.

Albireo Pharma Predictive Daily Indicators

Albireo Pharma intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Albireo Pharma stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.

Albireo Pharma Forecast Models

Albireo Pharma time-series forecasting models is one of many Albireo Pharma's stock analysis techniquest aimed to predict future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Albireo Pharma's historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.

About Albireo Stock Analysis

Stock analysis is the technique used by a trader or investor to examine and evaluate how Albireo Pharma prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Albireo shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas, a specific sector, or an individual Stock such as Albireo Pharma. By using and applying Albireo Stock analysis, traders can create a robust methodology for identifying Albireo entry and exit points for their positions.
Last ReportedProjected for 2022
EBITDA Margin(43.91) (47.38) 
Gross Margin 86.99  86.48 
Profit Margin(75.47) (81.43) 

Current Albireo Analysis - Recommendations

We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Albireo analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Albireo analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
Target PriceAdvice# of Analysts
75.8Strong Buy5Odds
Albireo Pharma current and past analyst recommendations published by a number of research institutions as well as average analyst consensus.
Most Albireo analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to helps potential investors understand Albireo stock's fair price compared to its market value. Analysts arrive at stock ratings after researching public financial statements of Albireo Pharma, talking to its executives and customers, or listening to Albireo conference calls.
Albireo Analyst Advice Details

Albireo Stock Analysis Indicators

Albireo Pharma stock analysis indicators help investors evaluate how Albireo Pharma stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Albireo Pharma shares will generate the highest return on investment. By understating and applying Albireo Pharma stock analysis, traders can identify Albireo Pharma position entry and exit signals to maximize returns.
Begin Period Cash Flow251272000.00
Total Stockholder Equity175608000.00
Country NameUSA
Total Liab126443000.00
Property Plant And Equipment Net668000.00
Retained Earnings-300850000.00
Cash And Short Term Investments248107000.00
Retained Earnings Total Equity-300850000.00
50 Day M A20.9904
Net Interest Income-13932000.00
Total Current Liabilities45347000.00
Common Stock Total Equity193000.00
Interest Expense13932000.00
Logo U R LimglogosUSALBO.png
Common Stock Shares Outstanding19220846.00
Total Cashflows From Investing Activities102922000.00
Other Current Assets17357000.00
Accounts Payable6516000.00
Net Debt-238103000.00
Currency CodeUSD
Other Operating Expenses164064000.00
Non Current Assets Total33121000.00
Liabilities And Stockholders Equity302051000.00
Non Currrent Assets Other15193000.00
Please continue to Trending Equities. Note that the Albireo Pharma information on this page should be used as a complementary analysis to other Albireo Pharma's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Portfolio Center module to all portfolio management and optimization tools to improve performance of your portfolios.

Complementary Tools for Albireo Stock analysis

When running Albireo Pharma price analysis, check to measure Albireo Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Albireo Pharma is operating at the current time. Most of Albireo Pharma's value examination focuses on studying past and present price action to predict the probability of Albireo Pharma's future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Albireo Pharma's price. Additionally, you may evaluate how the addition of Albireo Pharma to your portfolios can decrease your overall portfolio volatility.
Portfolio Rebalancing
Analyze risk-adjusted returns against different time horizons to find asset-allocation targets
Bond Directory
Find actively traded corporate debentures issued by US companies
Idea Analyzer
Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas
Price Ceiling Movement
Calculate and plot Price Ceiling Movement for different equity instruments
Aroon Oscillator
Analyze current equity momentum using Aroon Oscillator and other momentum ratios
Probability Of Bankruptcy
Get analysis of equity chance of financial distress in the next 2 years
Portfolio Anywhere
Track or share privately all of your investments from the convenience of any device
Companies Directory
Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals
Global Correlations
Find global opportunities by holding instruments from different markets
Portfolio Suggestion
Get suggestions outside of your existing asset allocation including your own model portfolios
Focused Opportunities
Build portfolios using our predefined set of ideas and optimize them against your investing preferences
Is Albireo Pharma's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Albireo Pharma. If investors know Albireo will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Albireo Pharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Market Capitalization
486.5 M
Quarterly Revenue Growth YOY
Return On Assets
Return On Equity
The market value of Albireo Pharma is measured differently than its book value, which is the value of Albireo that is recorded on the company's balance sheet. Investors also form their own opinion of Albireo Pharma's value that differs from its market value or its book value, called intrinsic value, which is Albireo Pharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Albireo Pharma's market value can be influenced by many factors that don't directly affect Albireo Pharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Albireo Pharma's value and its price as these two are different measures arrived at by different means. Investors typically determine Albireo Pharma value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Albireo Pharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.